← feed

Is NCT03267732 results overdue?

Yes — results are overdue. Primary completion was 2017-10-30; the FDAAA-801 reporting deadline (2018-10-30) passed 2791 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

NCT IDNCT03267732 ↗
SponsorEli Lilly and Company (INDUSTRY)
Public issuerELI LILLY & Co — LLY (CIK 0000059478) best-effort name match, 82% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-10-30 (ACTUAL)
Reporting deadline2018-10-30 (completion + 365d)
Days overdue2791
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 f1ce1e596256a677… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03267732. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →